Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| gp100 (PMEL) HLA-A*02:01 required for tebentafusp | >90% | Melanocytic lineage antigen | Wikipedia |
| LAG-3 RELATIVITY-047 population | 75-80% | LAG-3 >=1% on immune cells | Wikipedia |
| BRAF | 45-50% | V600 mutation | cBioPortal (TCGA) |
| PD-1 Not an expression prevalence | 30-40% | Objective response to PD-1 monotherapy (proxy) | Wikipedia |
| HER4 (ERBB4) Mutations increased kinase activity; mutant cells were sensitive to the ERBB inhibitor lapatinib | 19% | Somatic ERBB4 mutation, sequencing of 79 cutaneous metastatic melanomas | doi.org |
| KIT | 2-3% | KIT mutation (acral/mucosal enriched) | cBioPortal (TCGA) |
| CTLA-4 | n/a | Immune-cell target; no tumour prevalence | Wikipedia |
| PRAME | ~90% | IHC positivity in cutaneous melanoma | PMC |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
6 cell lines, 2 mouse models and 6 repositories are listed for this cancer. See them →